New Drug Approvals in China Reach Record High in 2023
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Novartis, and Takeda made…
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
Former director general of the Chinese Center for Disease Control and Prevention (CDC) and current chairman of the Chinese Foundation for Hepatitis Prevention and Control, Professor Yu Wang, weighs in…
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA…
Global pharma has been stepping up M&A activity in Asia while also looking to access Asian markets through local partners and tap into the region’s huge growth potential. As a…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
See our Cookie Privacy Policy Here
